Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Embattled Biotech Seagen Rockets On Rumors Merck Could Buy It ↗

June 17, 2022

The rumor emerges shortly after the company's former CEO was arrested.

Via Investor's Business Daily

Merck Shows Takeover Interest In Seagen: WSJ ↗

June 17, 2022

Via Benzinga

$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today ↗

June 16, 2022

Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 12.54% on an annualized basis producing an average annual return of 19.38%. Currently, Seagen has a market capitalization of...

Via Benzinga

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications ↗

June 13, 2022

Via Benzinga

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Seagen Inc.

Via Business Wire

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence ↗

May 09, 2022

Via Benzinga

Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim ↗

May 09, 2022

Siegall says he is going through a divorce and denied the claim.

Via Investor's Business Daily

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Genmab A/S

Via Business Wire

10 Biggest Price Target Changes For Monday ↗

June 06, 2022

Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.

Via Benzinga

ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma

June 03, 2022

From Seagen Inc.

Via Business Wire

Expert Ratings for Seagen ↗

April 29, 2022

Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings:

Via Benzinga

5 Growth Stocks to Buy Now ↗

May 27, 2022

EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks.

Via InvestorPlace

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

May 26, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer ↗

May 23, 2022

Via Benzinga

Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

May 23, 2022

From Seagen Inc.

Via Business Wire

Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest ↗

May 16, 2022

Clay Siegall and the board agreed it would be in investors' best interest if he resigned.

Via Investor's Business Daily

Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

May 16, 2022

From Seagen Inc.

Via Business Wire

Large Cap Biopharmaceuticals: Provide Growth, Value And Yield ↗

May 16, 2022

Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.

Via Talk Markets

103 Biggest Movers From Yesterday ↗

May 11, 2022

Gainers

Via Benzinga

77 Stocks Moving In Tuesday's Mid-Day Session ↗

May 10, 2022

Gainers

Via Benzinga

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

May 09, 2022

From Seagen Inc.

Via Business Wire

Looking Into Seattle Genetics's Return On Capital Employed ↗

May 04, 2022

According to Benzinga Pro data, during Q1, Seattle Genetics (NASDAQ:SGEN) posted sales of $426.46 million. Earnings were up 21.84%, but Seattle Genetics still reported an overall loss of $136.49...

Via Benzinga

4 Healthcare Funds With "Double Discounts" ↗

April 30, 2022

There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look...

Via Talk Markets

Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales ↗

April 29, 2022

Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.

Via Benzinga

Recap: Seagen Q1 Earnings ↗

April 28, 2022

Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by...

Via Benzinga

Seagen Reports First Quarter 2022 Financial Results

April 28, 2022

From Seagen Inc.

Via Business Wire

Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

April 28, 2022

From Seagen Inc.

Via Business Wire

Earnings Scheduled For April 28, 2022 ↗

April 28, 2022

Companies Reporting Before The Bell • PBF Energy (NYSE:PBF) is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion.

Via Benzinga

Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines

April 20, 2022

From Seagen Inc.

Via Business Wire

Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer ↗

April 13, 2022

The

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.